Cannabis Science Announces Participation in Major U.S.-Africa Policy Forum in Washington, DC

IRVINE, CA--(Marketwired - Sep 11, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that its senior executives will participate in the Constituency for Africa's (CFA) 2017 Ronald H. Brown African Affairs Series. The Series will be held September 18th-22nd in Washington, DC.

For over 26 years, CFA has established itself as one of the leading, non-partisan organizations focused on educating and mobilizing the American public and the African Diaspora in the U.S. on U.S.-Africa policy. As a result, CFA has helped to increase the level of cooperation and coordination among a broad-based coalition of individuals and organizations committed to the progress, development, and empowerment of Africa and African people worldwide.

The highlight of CFA's annual initiatives is the Ronald H. Brown African Affairs Series. The theme of this year's series is Mobilizing the Diaspora in Support of the U.S.-Africa Agenda, and the series is being organized by CFA in cooperation with the African Union Mission to the United States. The purpose of the 2017 Series is to bring together stakeholders from the U.S., Africa, and the African Diaspora to assess the U.S. Administration's Africa policy, and to identify challenges and opportunities in a number of key areas, including African healthcare infrastructure. The expected outcomes of the Series will include policy recommendations for the U.S. Administration and the African Union.

Mr. Raymond C. Dabney, Cannabis Science's President, CEO, Co-founder, and Director, and Dr. Allen Herman, CBIS' Chief Medical Officer, will deliver remarks at CFA's African Healthcare Infrastructure Roundtable on Tuesday, September 19th, and participate in a bi-partisan, senior-level U.S.-Africa Policy Forum on Thursday, September 21st. "I look forward to Cannabis Science's participation in this year's Ronald H. Brown African Affairs Series. This Series provides our company with the opportunity to engage with key U.S. and African stakeholders in government, private sector, civil society, and academia. These potential partnerships will enable Cannabis Science to accelerate our African drug-development initiative, as well as to build on our current collaborations for research and multi-center clinical trials," stated Mr. Dabney.

The theme of CFA's African Healthcare Infrastructure Roundtable is Reversing Africa's Brain Drain: The Role of the African Diaspora in Strengthening the Healthcare Infrastructure of Africa. This roundtable will explore strategies that invest in Africa's health workers, healthcare and social services infrastructure, logistics, surveillance and health information systems, healthcare governance, and drug supply systems. Confirmed speakers will include H.E. Arikana Chihombori, the African Union's Permanent Representative to the United States; Dr. Roscoe M. Moore, Jr., former Assistant United States Surgeon General and Rear Admiral, United States Public Health Service (Retired), and Interim Chairman of CFA's Board of Directors; Dr. John Nkengasong, Director of the Africa Centers for Disease Control and Prevention; and Professor Akin Abayomi, Principal Investigator (Academic) of the Global Emerging Pathogens Treatment Consortium (GET Africa), and Chief Pathologist and Head of the Division of Hematology at the University of Stellenbosch (South Africa).

Mr. Dabney will participate in a panel discussion on Investing in African Healthcare Infrastructure, and his remarks will focus on exploring drug development opportunities in Africa. As part of his remarks, Mr. Dabney will provide an update to stakeholders on specific activities the company is implementing that will positively impact the communities where the company operates, including cities throughout Africa. CBIS' comprehensive approach leverages the company's core competencies to contribute to overall economic development through education and training, food security and agriculture, technology and communications, and the implementation of public policies that create the enabling environment for the aforementioned.

For his remarks, Dr. Herman will provide an update on the operational strategy he developed for CFA's African Healthcare Infrastructure Committee, a network of Africa-focused healthcare experts launched during CFA's Ronald H. Brown Series in 2015.

CFA's U.S.-Africa Policy Forum will be the highlight of the 2017 Ronald H. Brown African Affairs Series. Policy Forum participants will discuss, debate, and ultimately agree on a strategy to improve U.S.-Africa cooperation in a number of key policy issues, including on strengthening Africa's healthcare infrastructure. The Policy Forum will be moderated by Ambassador Reuben E. Brigety, Dean of the Elliott School of International Affairs at The George Washington University, and former U.S. Representative to the African Union.

For more information on CFA's Ronald H. Brown African Affairs Series, please visit www.ronaldbrownseries.org.

Mr. Dabney is a Co-chair of the 2017 Ronald H. Brown African Affairs Series, and a member of the CFA Board of Directors. Cannabis Science is an official sponsor of this year's Series.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

 

CONTACT INFORMATION

  • Cannabis Science, Inc.
    Dr. Allen Herman
    Chief Medical Officer (CMO) 
    This email address is being protected from spambots. You need JavaScript enabled to view it.
    Tel: 1-888-263-0832

    Cannabis Science, Inc.
    Mr. Raymond C. Dabney
    President & CEO, Co-Founder
    This email address is being protected from spambots. You need JavaScript enabled to view it.
    Tel: 1-888-263-0832